

Analysis of AIHW data: [Disease expenditure in Australia 2019-20](#)

Total health system expenditure on prostate cancer was \$1.359b in 2019-2020, accounting for the highest costs of any single disease condition and of all cancer types (excluding non-melanoma skin cancers). This compares to total spending on prostate cancer of \$1.199b in 2018-19, a 13% year-on-year increase, with the cost of public hospital admissions alone increasing 33%. Prostate cancer accounted for 20% of PBS expenditure for all cancers.

Prostate Cancer – Expenditure in Hospital Areas 2019-20 (Total Spending \$591,999,715 – 12% increase on 2018-20)			
Private hospital services	Public hospital admitted patient	Public hospital emergency department	Public hospital outpatient
\$291,175,294 ¹	\$169,209,214 ²	\$326,970	\$131,288,237
Expenditure in 2018-19 (Total Spending \$530,708,820)			
\$252,677,658	\$127,651,061	\$303,262	\$150,076,839

Prostate Cancer – Expenditure in Primary Health Care Areas 2019-2020 (Total Spending \$633,327,766 - 11% increase on 2018-19)			
Allied health and other services	General practitioner services	Pharmaceutical Benefits Scheme	Dental expenditure
\$271,039	\$42,502,376	\$595,125,253 ³	\$25,429,098
Expenditure in 2018-19 (Total Spending \$572,549,333)			
\$270,407	\$39,645,754	\$505,119,040	\$27,514,133

Prostate Cancer – Expenditure in Referred Medical Service Areas 2019-20 (Total \$103,963,485 - 10% increase on 18-19)		
Medical imaging	Pathology	Specialist services
\$24,650,723	\$7,132,369	\$72,180,393
Expenditure in 2018-19 (Total Spending \$94,409,051)		
\$23,170,093	\$7,042,648	\$66,196,309

Public Hospital Emergency Department Expenditure increased by 8% between 2018-19 and 2019-20, while Public Hospital Outpatient Expenditure decreased by 13%. These changes in expenditure may be associated with pandemic impacts on access to the health system.

1. Private Hospital Service Expenditure increased by 15% on previous year.
2. Public Hospital Admitted Patient Expenditure increased by 33% on previous year.
3. Pharmaceutical Benefit Scheme Expenditure increased by 18% on previous year.